Markets:

Overview

News

Currencies

International

Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

49.57 +0.64 (+1.31%)

Official Closing Price Updated: 7:00 PM EST, Feb 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S Common Stock

< Previous 1 2

...

30 31 32 33 34 35 36 37 38

...

99 100 Next >

Wegovy, Zepbound Just Got Cheaper: Cigna Sets $200 Monthly Limit For Weight-Loss Drug Users ↗

May 22, 2025

Cigna’s Evernorth has reached agreements with Eli Lilly and Novo Nordisk to reduce prices for GLP-1 weight-loss drugs Wegovy and Zepbound

Via Stocktwits

Best Healthcare Stocks: Eli Lilly vs. Novo Nordisk ↗

May 21, 2025

Via The Motley Fool

10 Health Care Stocks With Whale Alerts In Today's Session ↗

May 20, 2025

Via Benzinga

Why Novo Nordisk Stock Popped on Tuesday ↗

May 20, 2025

If you can't beat Novo Nordisk, maybe you should join 'em?

Via The Motley Fool

2 Fantastic Beaten-Down Growth Stocks Down 40% and 45% to Buy ↗

May 20, 2025

These two stocks are poised for near-term and long-term upside.

Via The Motley Fool

The End Of The Diabetes Industry? This Small Cap Could Upend The Business Models of Pharma Giants ↗

May 19, 2025

is it the end of the diabetes industry? Here's a small cap that could upend the business models of pharma giants...

Via Benzinga

MarketBeat Week in Review – 05/12 - 05/16

May 17, 2025

Stocks had a strong week on a potential U.S.-China trade deal and cooler inflation data, but volatility may remain as investors shift focus to tax cuts

Via MarketBeat

NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) – A Strong Growth Stock with Technical Breakout Potential ↗

May 17, 2025

NOVO-NORDISK (NYSE:NVO) is a strong growth stock with solid fundamentals and a promising technical setup, offering potential for a breakout.

Via Chartmill

On Holding on Fire ↗

May 17, 2025

A consumer goods company hit 40% yearly revenue growth. In this environment?

Via The Motley Fool

Topics Bonds Government

3 Stocks That Will Profit From Trump's Drug Price Cut ↗

May 16, 2025

Trump's EO aims to lower US drug prices by using leverage of public programs (like Medicare) to force accountability. Big pharma may be hit hardest.

Via Benzinga

Topics Government

Why Novo Nordisk Stock Just Slipped ↗

May 16, 2025

Investors may get a second bite at the apple, and a second chance to buy this GLP-1 drug leader at a discount price.

Via The Motley Fool

Novo Nordisk Sheds 4% After Ousting CEO As Eli Lilly Rivalry Slams Stock Price ↗

May 16, 2025

Novo Nordisk said Friday it will replace its CEO, citing a sharp tumble for Novo shares amid growing competition.

Via Investor's Business Daily

Ozempic Maker Novo Nordisk Looks For New Chief, Jørgensen Steps Down From CEO Role ↗

May 16, 2025

Novo Nordisk CEO steps down after pressure from shareholders. Former CEO to join board as observer. Company remains optimistic amid mixed signals.

Via Benzinga

Novo Nordisk CEO Lars Jørgensen Steps Down Amid Challenges, Retail Chatter Spikes ↗

May 16, 2025

The company said it would announce the next CEO in “due course,” but did not provide a more definite timeline.

Via Stocktwits

Wall Street Expects This Obesity Drug Stock to Skyrocket 35% Over the Next 12 Months ↗

May 16, 2025

Via The Motley Fool

Is It Time to Buy the Dip in Novo Nordisk Stock?

May 15, 2025

Novo Nordisk stock is down nearly 50% in 2025 as competition in the GLP-1 space continues to mount, but the fundamental case for the NVO stock is growing

Via MarketBeat

Topics Government

Novo Nordisk's Ozempic Weight Loss Jabs Could Boost UK Economy By $6 Billion, Study Finds ↗

May 14, 2025

Weight loss drugs like semaglutide could add £4.5 billion to the UK economy annually, boosting productivity and reducing alcohol use, though high costs may limit broad access.

Via Benzinga

Topics Economy

Novo Nordisk Inks $2.2 Billion Deal With Septerna To Develop Oral Weight Loss And Diabetes Drugs ↗

May 14, 2025

Novo Nordisk and Septerna enter $2.2 billion deal to develop oral small-molecule therapies targeting obesity, diabetes, and cardiometabolic diseases.

Via Benzinga

Novo Nordisk Inks A Major Obesity Deal, Sending Shares Of New Partner Septerna Skyrocketing ↗

May 14, 2025

The deal is worth up to $2.2 billion, including more than $200 million in upfront and near-term payments.

Via Investor's Business Daily

Novo Nordisk Inks $2.2B Deal With Septerna: Retail’s Thrilled ↗

May 14, 2025

Septerna CEO Jeffrey Finer said that the collaboration allows the company to create multiple oral medicines and provides the operational flexibility and resources to advance its portfolio of other...

Via Stocktwits

Topics Artificial Intelligence

Why Weight-Loss Developer Stocks Tumbled on Tuesday ↗

May 13, 2025

Via The Motley Fool

Topics Government

Is the Fed on the Right Track? ↗

May 13, 2025

Via The Motley Fool

Topics Economy World Trade

Trump’s ‘Most Favored Nation’ Drug Plan Likely To Face Pushback, JP Morgan Analysts Say ↗

May 12, 2025

JPMorgan analysts said President Trump’s "most favored nation" drug pricing order is unlikely to move forward without Congressional support and will likely face legal and industry resistance, limiting...

Via Stocktwits

Topics ETFs Government Stocks

Big News! U.S. and China Trade Deal Shakes Up Markets ↗

May 12, 2025

Stocks are soaring today on the hope that the trade tensions between the U.S. and China are behind us.

Via The Motley Fool

Topics World Trade

Novo Nordisk's Sogroya Supports Effective Weekly Alternative To Daily Hormone Therapy Across Three Growth Disorders ↗

May 12, 2025

Novo Nordisk reports phase 3 data showing weekly Sogroya matched or outperformed daily hormone therapy in multiple pediatric growth disorders.

Via Benzinga

Mark Cuban Slams Charlie Kirk Over Drug Price Debate, Says PBMs — Not Big Pharma — Are The Real Villains: 'For Your Company...Ask Your PBM For A List Of Claims' ↗

May 12, 2025

Mark Cuban, the billionaire entrepreneur, challenged Trump-supporter and political activist Charlie Kirk's stance on high drug prices, asserting that Pharmacy Benefit Managers (PBMs) are the main...

Via Benzinga

Trump's New Drug Pricing Executive Order Could Rattle Pharma Stocks, With Price Cuts Of Up To 80%: Novo Nordisk, Pfizer And J&J Fall In Premarket ↗

May 12, 2025

What Happened: On Sunday, President Donald Trump announced on Truth Social that he plans to sign what he called the "most consequential executive order" in U.S. history, aimed at lowering prescription...

Via Benzinga

Topics Government

Eli Lilly's Zepbound Shows Superior Weight Loss Over Novo Nordisk's Wegovy In Head-To-Head Trial ↗

May 12, 2025

Eli Lilly and Company's Zepbound demonstrated superior weight reduction compared to Novo Nordisk's Wegovy in a 72-week head-to-head trial.

Via Benzinga

Eli Lilly's Zepbound Outperforms Wegovy In New Obesity Trial, But Trump's Drug Pricing Plan Keeps Retail Traders Wary ↗

May 11, 2025

Eli Lilly’s Zepbound led to 47% greater weight loss than Wegovy in a 72-week trial, yet retail sentiment turned bearish on Stocktwits amid heightened scrutiny on drug pricing following Trump’s vow to...

Via Stocktwits

Topics Government

Trump Says Prescription Drug Prices Set To Drop By 30% To 80% 'Almost Immediately' Thanks To 'Most Favored Nation' Plan, Mark Cuban Urges President To 'Force Transparency' ↗

May 11, 2025

Trump vows to slash drug prices with new executive order, potentially dropping them by 30-80%.

Via Benzinga

Topics Government

< Previous 1 2

...

30 31 32 33 34 35 36 37 38

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Novo Nordisk A/S Common Stock (NY:NVO)

All News about Novo Nordisk A/S Common Stock

Starting at $3.75/week.

Subscribe Today